SEC Form 3 · accession 0001282930-26-000012

Electra Therapeutics, Inc. · ETRA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Carl L Gordon

Director

Period of report

Sep 18, 2026

Accepted (ET)

Sep 18, 2026 · 4:16 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0002088082

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Convertible Preferred Stock^F2,F1	—	holding	—	—	—	—	—	Common Stock	2,002,310	—	I
Series B Convertible Preferred Stock^F2,F1	—	holding	—	—	—	—	—	Common Stock	1,087,934	—	I
Series C Convertible Preferred Stock^F3,F1	—	holding	—	—	—	—	—	Common Stock	758,279	—	I
Series C Convertible Preferred Stock^F2,F1	—	holding	—	—	—	—	—	Common Stock	1,703,314	—	I
Director Stock Option (right to buy)^F4	$15.00	holding	—	—	—	—	Sep 16, 2036	Common Stock	22,632	—	D

Explanation of responses

F1Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") will automatically convert into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.
F2These securities are held directly by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII.
F3These securities are held directly by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis.
F4The shares subject to this option shall vest on the earlier of September 17, 2027 and the date of the next annual meeting of the Issuer's stockholders